Developing novel treatments for mental health via psychedelic therapies...

Woke Pharmaceuticals is on a mission to change the status quo in the treatment of mental health.

Woke is focused on working with leading universities and research institutes to develop psychedelic therapies to help those who struggle with mental health.

We are committed to Innovation

In addition to developing proprietary synthetic psilocybin formulations, we are pioneering novel drug discovery.

To improve patients' psychedelic experience, we are developing dosing and delivery methods for psychedelics.

The company is pursuing global patents at every opportunity, with a foundational provisional patent application already filed and many more on the way.

Latest Announcements


September 2022 Corporate Presentation

Read More
Press Release

Provisional Patent Application

Read More
Press Release

Woke and Swinburne University Sign Memorandum of Understanding to Develop WP002 Psilocybin-assisted Psychotherapy Phase IIB trial in Treatment-Resistant Depression

Read More
Press Release

Woke and QIMR Berghofer Sign Letter of Intent for Clinical Trial of WP002 Psilocybin in Prolonged Grief

Read More

Research & Development

Initial focus on psilocybin for depression based on evidence of efficacy. Proprietary formulations to enhance release profile of active drug and secure Intellectual Property

CandidateMoleculeDeliveryIndicationDevelopment StatusPartners
WP001Psilocybin (low dose)Rapid release CapsuleModerate DepressionCommencing Phase IIB trial in Q4 CY2022 Monash University MMIC Maquaire University
WP002Psilocybin (high dose)Rapid release TabletTreatment-Resistent DepressionCommencing Phase IIB trial in Q4 CY2022 Monash University MMIC Imperial College London Drug Science (UK) Swinburne University
WP002Psilocybin (high dose)Rapid release TabletProlonged griefCommencing feasibility trial in Q4 CY2022 QIMR-Berghofer
WP003LSD (novel analogue)EnhancedAnxiety, Substance Abuse, PTSDDrug discovery University of Western Australia

Partnerships with leading clinicians and formulation experts

The Market | Unmet Medical Need Continues to Grow

Over 700 million people are affected globally with some sort of mental illness, eg: depression, anxiety, PTSD, addiction or eating disorder

Source: The World Health Organisation

Global economic costs due to mental heath disorders estimated to be USD$800 Billion direct and US$1.7 Billion indirect

Source: National Centre for Biotechnology Information


25% of adults in the world will be affected by mental or neurological disorders at some point in their lives

Source: World Health Organisation

ACN: 651 290 729

Address: Suite 301, 10 Bridge St, Sydney NSW 2000 Australia